Anling Hu

State Key Laboratory Of Discovery And Utilization Of Functional Components In Traditional Chinese Medicine
Guiyang, 550014, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Dual inhibition of tubulin and DNMT by the novel letermovir derivative H62 blocks leukemia.

Dual inhibition of tubulin and DNMT by the novel letermovir derivative H62 blocks leukemia.

Journal: Biochemical pharmacology

Published: April 21, 2026

The novel δ,γ-biscarboline derivative T2 suppresses erythroleukemia through inhibition of AKR1B1 in the fructose metabolic reprogramming.

The novel δ,γ-biscarboline derivative T2 suppresses erythroleukemia through inhibition of AKR1B1 in the fructose metabolic reprogramming.

Journal: Chemico-biological interactions

Published: December 28, 2025

Yuxingcao formula suppresses acute erythroleukemia through inhibition of AKT1 and FLI1.

Yuxingcao formula suppresses acute erythroleukemia through inhibition of AKT1 and FLI1.

Journal: Fitoterapia

Published: September 01, 2025

Vitamin D3 and its active form calcitriol suppress erythroleukemia through upregulation of CHAC1 and downregulation of NOTCH1.

Vitamin D3 and its active form calcitriol suppress erythroleukemia through upregulation of CHAC1 and downregulation of NOTCH1.

Journal: Medical oncology (Northwood, London, England)

Published: January 16, 2025

The Astragalus Membranaceus Herb Attenuates Leukemia by Inhibiting the FLI1 Oncogene and Enhancing Anti-Tumor Immunity.

The Astragalus Membranaceus Herb Attenuates Leukemia by Inhibiting the FLI1 Oncogene and Enhancing Anti-Tumor Immunity.

Journal: International journal of molecular sciences

Published: November 12, 2024

FLI1 Induces Plaque Psoriasis and Its Inhibition Attenuates Disease Progression.

FLI1 Induces Plaque Psoriasis and Its Inhibition Attenuates Disease Progression.

Journal: Journal of inflammation research

Published: October 22, 2024

UM171 suppresses breast cancer progression by inducing KLF2.

UM171 suppresses breast cancer progression by inducing KLF2.

Journal: Breast cancer research and treatment

Published: February 07, 2024

An intricate regulatory circuit between FLI1 and GATA1/GATA2/LDB1/ERG dictates erythroid vs. megakaryocytic differentiation.

An intricate regulatory circuit between FLI1 and GATA1/GATA2/LDB1/ERG dictates erythroid vs. megakaryocytic differentiation.

Journal: Molecular medicine reports

Published: December 08, 2023

FLI1 induces erythroleukemia through opposing effects on UBASH3A and UBASH3B expression.

FLI1 induces erythroleukemia through opposing effects on UBASH3A and UBASH3B expression.

Journal: BMC cancer

Published: July 21, 2023

FLI1 Regulates Histamine Decarboxylase Expression to Control Inflammation Signaling and Leukemia Progression.

FLI1 Regulates Histamine Decarboxylase Expression to Control Inflammation Signaling and Leukemia Progression.

Journal: Journal of inflammation research

Published: December 22, 2022

Lovastatin inhibits erythroleukemia progression through KLF2-mediated suppression of MAPK/ERK signaling.

Lovastatin inhibits erythroleukemia progression through KLF2-mediated suppression of MAPK/ERK signaling.

Journal: BMC cancer

Published: October 04, 2022

FLI1 accelerates leukemogenesis through transcriptional regulation of pyruvate kinase-L/R and other glycolytic genes.

FLI1 accelerates leukemogenesis through transcriptional regulation of pyruvate kinase-L/R and other glycolytic genes.

Journal: Medical oncology (Northwood, London, England)

Published: August 16, 2022

Showing 1-12 of 20

Last Updated: 09/26/2026